Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
SSE:603811.SS
9.6 (CNY) • At close June 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 714.369 | 671.627 | 654.973 | 693.965 | 758.132 | 681.228 | 545.766 | 340.892 | 321.223 | 316.954 | 320.232 | 266.056 | 255.433 | 215.281 |
| Cost of Revenue
| 217.643 | 240.598 | 206.815 | 192.604 | 194.171 | 183.118 | 194.821 | 163.246 | 157.056 | 148.598 | 156.096 | 148.021 | 148.924 | 138.323 |
| Gross Profit
| 496.727 | 431.029 | 448.158 | 501.361 | 563.961 | 498.11 | 350.945 | 177.647 | 164.167 | 168.356 | 164.136 | 118.036 | 106.509 | 76.958 |
| Gross Profit Ratio
| 0.695 | 0.642 | 0.684 | 0.722 | 0.744 | 0.731 | 0.643 | 0.521 | 0.511 | 0.531 | 0.513 | 0.444 | 0.417 | 0.357 |
| Reseach & Development Expenses
| 47.085 | 47.144 | 44.304 | 39.715 | 31.794 | 29.571 | 26.26 | 13.126 | 15.172 | 15.909 | 10.831 | 11.132 | 9.169 | 0 |
| General & Administrative Expenses
| 20.804 | 15.523 | 23.415 | 28.769 | 20.647 | 15.866 | 12.64 | 15.452 | 12.625 | 12.847 | 16.199 | 36.856 | 31.942 | 29.586 |
| Selling & Marketing Expenses
| 149.316 | 121.54 | 180.693 | 200.563 | 272.122 | 267.352 | 167.218 | 45.796 | 35.119 | 45.138 | 45.14 | 32.199 | 33.008 | 26.981 |
| SG&A
| 170.12 | 137.063 | 204.108 | 229.331 | 292.769 | 283.219 | 179.859 | 61.248 | 47.745 | 57.986 | 61.339 | 69.055 | 64.95 | 56.567 |
| Other Expenses
| 58.316 | 72.913 | 63.753 | 67.603 | 54.263 | 28.405 | 0.188 | 3.488 | 3.799 | 4.315 | 2.149 | 2.229 | 2.145 | 0.835 |
| Operating Expenses
| 275.521 | 257.12 | 312.165 | 336.65 | 378.826 | 341.194 | 241.722 | 100.285 | 88.209 | 97.884 | 94.644 | 71.322 | 66.875 | 57.984 |
| Operating Income
| 221.206 | 173.909 | 164.429 | 198.538 | 190.362 | 154.285 | 112.706 | 78.829 | 75.715 | 64.542 | 63.226 | 40.822 | 32.309 | 14.671 |
| Operating Income Ratio
| 0.31 | 0.259 | 0.251 | 0.286 | 0.251 | 0.226 | 0.207 | 0.231 | 0.236 | 0.204 | 0.197 | 0.153 | 0.126 | 0.068 |
| Total Other Income Expenses Net
| -3.072 | 0.153 | -0.588 | -1.034 | -1.468 | -1.341 | -2.053 | 3.488 | 3.217 | 3.621 | 1.833 | 1.739 | -5.122 | 0.164 |
| Income Before Tax
| 218.134 | 174.062 | 163.841 | 197.503 | 188.894 | 152.944 | 112.894 | 82.317 | 79.221 | 68.163 | 65.059 | 42.561 | 33.7 | 14.834 |
| Income Before Tax Ratio
| 0.305 | 0.259 | 0.25 | 0.285 | 0.249 | 0.225 | 0.207 | 0.241 | 0.247 | 0.215 | 0.203 | 0.16 | 0.132 | 0.069 |
| Income Tax Expense
| 17.348 | 12.012 | 2.659 | 26.275 | 23.943 | 21.982 | 15.499 | 13.078 | 11.052 | 10.458 | 11.205 | 6.063 | 4.399 | 1.484 |
| Net Income
| 200.701 | 162.897 | 161.583 | 170.797 | 165.144 | 131.392 | 96.912 | 69.238 | 68.169 | 57.705 | 53.854 | 36.498 | 29.301 | 13.351 |
| Net Income Ratio
| 0.281 | 0.243 | 0.247 | 0.246 | 0.218 | 0.193 | 0.178 | 0.203 | 0.212 | 0.182 | 0.168 | 0.137 | 0.115 | 0.062 |
| EPS
| 0.61 | 0.5 | 0.49 | 0.52 | 0.5 | 0.4 | 0.3 | 0.32 | 0.28 | 0.23 | 0.22 | 0.15 | 0.17 | 0.076 |
| EPS Diluted
| 0.61 | 0.5 | 0.49 | 0.52 | 0.5 | 0.4 | 0.3 | 0.32 | 0.28 | 0.23 | 0.22 | 0.15 | 0.17 | 0.076 |
| EBITDA
| 325.056 | 267.443 | 235.34 | 257.061 | 241.725 | 175.555 | 131.08 | 96.243 | 93.491 | 84.266 | 80.384 | 58.284 | 52.209 | 30.84 |
| EBITDA Ratio
| 0.455 | 0.398 | 0.359 | 0.37 | 0.319 | 0.258 | 0.24 | 0.282 | 0.291 | 0.266 | 0.251 | 0.219 | 0.204 | 0.143 |